June 13, 2018
The New Bayer and its Pharma Business
By: Patricia Van Arnum, DCAT Editorial Director

Bayer’s completion of its $63-billion acquisition of Monsanto, an agrochemical and seed company, fortifies the company’s plan of becoming a pure-play life-sciences company focused on pharmaceuticals, crop science, consumer healthcare, and animal health. But with such a large play into crop protection, where does its pharmaceuticals business now stand?

With the acquisition, Bayer’s crop-science business will now be the largest piece of Bayer by revenue, eclipsing its pharmaceutical business, which accounted for nearly 50% of the company’s sales in 2017.  DCAT Value Chain Insights  examines the new Bayer.
Optimizing the Pharma Customer Supplier Relationship
By: Patricia Van Arnum, DCAT Editorial Director

How can pharmaceutical companies and suppliers best partner to achieve cost-efficiencies and drive value? A preview of DCAT Sharp Sourcing, to be held June 26, highlights best practices.

The program features collaborative approaches with insight from Pfizer, Johnson & Johnson, Merck & Co., and Teva Pharmaceuticals. The program will also examine how digital tools, such as blockchain technology, artificial intelligence, and advanced analytics, are changing the way companies interact with customers and suppliers.
VCI Headliners: Top Industry News
About the Editor
Patricia Van Arnum has more than 20 years of experience as a business and science editor, covering the chemical, pharmaceutical, biopharmaceutical, and fine-chemicals industries. Ms. Van Arnum was Executive Editor of Pharmaceutical Technology from 2006 to 2014 and Executive Editor of ICIS Chemical Business and Chemical Market Reporter ( CMR ) from 1995 to 2005.
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .